CareDx to Acquire Naveris for $260M to Expand Into HPV-Driven Cancer MRD Monitoring

Why It Matters

The transaction gives CareDx a foothold in liquid‑biopsy‑based cancer surveillance, a high‑margin specialty where early detection can drive better outcomes and recurring revenue. It positions the company to capture a growing share of HPV‑driven cancer management, a segment poised for broader clinical adoption.

Key Takeaways

• CareDx pays $160M cash, up to $100M milestones.
• Naveris' NavDx test targets HPV-driven head & neck, anal cancers.
• Naveris generated $34M 2025 revenue, 30‑40% annual growth forecast.
• Over 130,000 liquid biopsies performed to date.
• Acquisition adds 100 employees and two high‑complexity labs.

Pulse Analysis

HPV‑driven malignancies such as head‑and‑neck and anal cancers are on the rise, and clinicians are seeking more precise tools than imaging to monitor disease recurrence. Liquid biopsy, which captures circulating tumor DNA, offers a non‑invasive, repeatable method for detecting molecular residual disease (MRD). Naveris’ NavDx test leverages tumor‑tissue‑modified viral DNA, delivering high sensitivity for viral‑mediated tumors and positioning it as a potential new standard of care for post‑treatment surveillance.

CareDx, historically a leader in transplant‑related diagnostics, is leveraging its expertise in complex clinical workflows and reimbursement strategies to enter the oncology space. By integrating Naveris’ technology, CareDx can apply its proven model of evidence generation and payer engagement to accelerate adoption of NavDx across specialty oncology markets. The acquisition also diversifies CareDx’s revenue base, reducing reliance on transplant testing while tapping into a segment projected to grow at double‑digit rates as precision medicine expands.

Financially, the deal adds a rapidly scaling $34 million revenue line with 30‑40% projected growth, and the $12 million Q1 2026 earnings from Naveris are expected to be margin‑positive, preserving CareDx’s 2026 AEBITDA guidance. The integration of 100 scientists, clinicians, and two CLIA‑certified labs provides the infrastructure needed for nationwide rollout. As insurers increasingly reimburse MRD testing, CareDx’s acquisition could translate into recurring test volumes and a durable competitive advantage in the emerging liquid‑biopsy market.

Deal Summary

CareDx announced a definitive agreement to acquire precision oncology firm Naveris for up to $260 million, including $160 million cash up‑front and $100 million contingent on milestones. The deal will broaden CareDx’s portfolio into HPV‑driven cancer MRD monitoring and is slated to close in Q3 2026.